keyword
MENU ▼
Read by QxMD icon Read
search

helicobacter pylori eradication in Japan

keyword
https://www.readbyqxmd.com/read/29609065/low-incidence-of-esophageal-adenocarcinoma-after-eradication-of-helicobacter-pylori-in-japan
#1
Susumu Take, Motowo Mizuno, Kuniharu Ishiki, Fumihiro Hamada, Tomowo Yoshida, Kenji Yokota, Hiroyuki Okada
No abstract text is available yet for this article.
March 30, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29605555/randomized-controlled-trial-ppi-based-triple-therapy-containing-metronidazole-versus-clarithromycin-as-first-line-treatment-for-helicobacter-pylori-in-adolescents-and-young-adults-in-japan
#2
Katushiro Mabe, Masumi Okuda, Shogo Kikuchi, Kenji Amagai, Rie Yoshimura, Mototsugu Kato, Naoya Sakamoto, Masahiro Asaka
BACKGROUND/AIMS: Treating Helicobacter pylori infection in young people is effective for preventing gastric cancer. This study compares the efficacy of triple therapies in adolescents and young adults in Japan. METHODS: This multicenter, randomized trial was conducted between February 2012 and March 2015. Infected participants were stratified into adolescents (13-19 years) and young adults (20-39 years). They were randomly assigned to a clarithromycin based (PAC) or metronidazole based (PAM) triple therapy for 1 week...
March 28, 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/29515585/influence-of-intestinal-indigenous-microbiota-on-intrafamilial-infection-by-helicobacter-pylori-in-japan
#3
Takako Osaki, Cynthia Zaman, Hideo Yonezawa, Yingsong Lin, Masumi Okuda, Eriko Nozaki, Fuhito Hojo, Satoshi Kurata, Tomoko Hanawa, Shogo Kikuchi, Shigeru Kamiya
Helicobacter pylori is a causative pathogen of chronic gastritis, gastric ulcer disease, and gastric cancer. Humans are known to be a natural host for H. pylori and tend to acquire the pathogen before the age of 5 years. The infection may then persist lifelong if eradication therapy is not applied. One of the modes of transmission of H. pylori is between family members, and therefore, the presence of infected family members is an important risk factor in children. However, other environmental factors have not been fully analyzed...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29504247/anti-helicobacter-pylori-therapy-in-localized-gastric-mucosa-associated-lymphoid-tissue-lymphoma-a-prospective-nationwide-multicenter-study-in-japan
#4
Katsuya Sugizaki, Akira Tari, Yasuhiko Kitadai, Ichiro Oda, Shotaro Nakamura, Tadashi Yoshino, Toshiro Sugiyama
BACKGROUND: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. MATERIALS AND METHODS: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H...
April 2018: Helicobacter
https://www.readbyqxmd.com/read/29282636/vonoprazan-a-novel-and-potent-alternative-in-the-treatment-of-acid-related-diseases
#5
REVIEW
Xiaoxiao Yang, Yueyue Li, Yiyuan Sun, Mingming Zhang, Chuanguo Guo, Iqtida Ahmed Mirza, Yan-Qing Li
Although proton pump inhibitors (PPIs) have been used widely, acid-related diseases are still associated with a huge burden on the health care system. Recently, the efficacy and safety of a new acid suppressant named vonoprazan in the treatment of acid-related diseases have been evaluated by a series of studies. As a novel potassium-competitive acid blocker, vonoprazan may provide reversible acid suppression by preventing K+ from binding to gastric H+ /K+ -ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H...
February 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29110085/safety-of-first-line-triple-therapy-with-a-potassium-competitive-acid-blocker-for-helicobacter-pylori-eradication-in-children
#6
Chika Kusano, Takuji Gotoda, Sho Suzuki, Hisatomo Ikehara, Mitsuhiko Moriyama
BACKGROUND: Helicobacter pylori infection is a risk factor for gastric cancer, and it has been reported that eradication of H. pylori is effective for preventing such cancer. Recently, H. pylori eradication has been performed in children as first-line therapy against gastric cancer. Here, we report use of triple therapy with a potassium-competitive acid blocker (P-CAB) for H. pylori eradication in children. METHODS: H. pylori infection testing and eradication therapy began in fiscal year 2015 in junior high school students located in Yurihonjo city and Nikaho city, Akita prefecture, Japan...
November 7, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28854276/a-significant-increase-in-the-pepsinogen-i-ii-ratio-is-a-reliable-biomarker-for-successful-helicobacter-pylori-eradication
#7
Hiroki Osumi, Junko Fujisaki, Takanori Suganuma, Yusuke Horiuchi, Masami Omae, Toshiyuki Yoshio, Akiyoshi Ishiyama, Tomohiro Tsuchida, Kazumasa Miki
BACKGROUND: Helicobacter pylori (H. pylori) eradication is usually assessed using the 13C-urea breath test (UBT), anti-H. pylori antibody and the H. pylori stool antigen test. However, a few reports have used pepsinogen (PG), in particular, the percentage change in the PG I/II ratio. Here, we evaluated the usefulness of the percentage changes in serum PG I/II ratios for determining the success of eradication therapy for H. pylori. MATERIALS AND METHODS: In total, 650 patients received eradication therapy from October 2008 to March 2013 in our Cancer Institute Hospital...
2017: PloS One
https://www.readbyqxmd.com/read/28817628/effectiveness-of-helicobacter-pylori-eradication-in-the-prevention-of-primary-gastric-cancer-in-healthy-asymptomatic-people-a-systematic-review-and-meta-analysis-comparing-risk-ratio-with-risk-difference
#8
REVIEW
Takeshi Seta, Yoshimitsu Takahashi, Yoshinori Noguchi, Satoru Shikata, Tatsuya Sakai, Kyoko Sakai, Yukitaka Yamashita, Takeo Nakayama
BACKGROUND: Helicobacter pylori infection is strongly associated with gastric cancer occurrence. However, it is unclear whether eradication therapy reduces the risk of gastric cancer occurrence. We evaluated whether H. pylori eradication reduces the risk of primary gastric cancer by using both risk ratio (RR) and risk difference (RD). METHODS: Searches of PubMed, EMBASE, Google scholar, the Cochrane Library, and the Japan Medical Abstracts Society as well as those registered in databases of the Cochrane Central Register of Controlled Trials, metaRegister of Controlled Trials, ClinicalTrials...
2017: PloS One
https://www.readbyqxmd.com/read/28814829/antibiotic-susceptibility-heteroresistance-and-updated-treatment-strategies-in-helicobacter-pylori-infection
#9
REVIEW
Maria Teresa Mascellino, Barbara Porowska, Massimiliano De Angelis, Alessandra Oliva
In this review, we discuss the problem of antibiotic resistance, heteroresistance, the utility of cultures and antibiotic susceptibility tests in Helicobacter pylori ( Hp ) eradication, as well as the updated treatment strategies for this infection. The prevalence of antibiotic resistance is increasing all over the world, especially for metronidazole and clarithromycin, because of their heavy use in some geographical areas. Heteroresistance (simultaneous presence of both susceptible and resistant strains in different sites of a single stomach) is another important issue, as an isolate could be mistakenly considered susceptible if a single biopsy is used for antimicrobial tests...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28771894/effect-on-helicobacter-pylori-eradication-therapy-against-gastric-cancer-in-japan
#10
Momoko Tsuda, Masahiro Asaka, Mototsugu Kato, Rumiko Matsushima, Kenji Fujimori, Kozo Akino, Shogo Kikuchi, Yingsong Lin, Naoya Sakamoto
BACKGROUND: In Japan, there have been approximately 50 000 deaths from gastric cancer annually for over 40 years with little variation. It has been reported that most gastric cancers in Japan are caused by Helicobacter pylori infection. H. pylori eradication therapy was approved for patients with chronic gastritis by the Japanese national health insurance scheme in February 2013 for patients with an endoscopic diagnosis of chronic gastritis is positive for H. pylori. We examined the effect on gastric cancer death rate 4 years after expansion of health insurance coverage...
October 2017: Helicobacter
https://www.readbyqxmd.com/read/28762251/helicobacter-pylori-management-in-asean-the-bangkok-consensus-report
#11
REVIEW
Varocha Mahachai, Ratha-Korn Vilaichone, Rapat Pittayanon, Jarin Rojborwonwitaya, Somchai Leelakusolvong, Monthira Maneerattanaporn, Peranart Chotivitayatarakorn, Sombat Treeprasertsuk, Chomsri Kositchaiwat, Pises Pisespongsa, Pisaln Mairiang, Aziz Rani, Alex Leow, Swe Mon Mya, Yi-Chia Lee, Sengdao Vannarath, Bouachanh Rasachak, Oung Chakravuth, Moe Myint Aung, Tiing-Leong Ang, Jose D Sollano, Duc Trong Quach, Inchaya Sansak, Olarn Wiwattanachang, Piyathida Harnsomburana, Ari Fahrial Syam, Yoshio Yamaoka, Kwong-Ming Fock, Khean-Lee Goh, Kentaro Sugano, David Graham
Helicobacter pylori (H. pylori) infection remains to be the major cause of important upper gastrointestinal diseases such as chronic gastritis, peptic ulcer, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. H. pylori management in ASEAN: the Bangkok consensus report gathered key opinion leaders for the region to review and evaluate clinical aspects of H. pylori infection and to develop consensus statements, rationales, and grades of recommendation for the management of H. pylori infection in clinical practice in ASEAN countries...
January 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28760790/impact-of-health-insurance-coverage-for-helicobacter-pylori-gastritis-on-the-trends-in-eradication-therapy-in-japan-retrospective-observational-study-and-simulation-study-based-on-real-world-data
#12
Shinzo Hiroi, Kentaro Sugano, Shiro Tanaka, Koji Kawakami
OBJECTIVES: To explore the prevalence of Helicobacter pylori infection in Japan and the trends of its eradication therapy before and after the changes of the insurance coverage policy, first started in 2000, and expanded to cover H. pylori-positive gastritis in 2013. The impacts that the changes brought were estimated. METHODS: In this retrospective observational study and simulation study based on health insurance claims data, product sales data and relevant studies, individuals who received triple therapy (amoxicillin, clarithromycin, proton-pump inhibitors or potassium-competitive acid blockers) were defined as the first-time patients for H...
July 31, 2017: BMJ Open
https://www.readbyqxmd.com/read/28725170/helicobacter-pylori-infection-status-had-no-influence-on-upper-gastrointestinal-symptoms-a-cross-sectional-analysis-of-3-005-japanese-subjects-without-upper-gastrointestinal-lesions-undergoing-medical-health-checkups
#13
Tomomi Yoshioka, Eri Takeshita, Yasuhisa Sakata, Megumi Hara, Kayo Akutagawa, Natsuko Sakata, Hiroyoshi Endo, Takashi Ohyama, Keiji Matsunaga, Yuichiro Tanaka, Shinpei Shirai, Yoichiro Ito, Nanae Tsuruoka, Ryuichi Iwakiri, Motoyasu Kusano, Kazuma Fujimoto
BACKGROUND: This study aimed to evaluate the influence of Helicobacter pylori infection and its eradication on the upper gastrointestinal symptoms of relatively healthy Japanese subjects. METHODS: A total of 3,005 subjects (male/female: 1,549/1,456) undergoing medical health checkups were enrolled in the present study, at five hospitals in Saga, Japan, from January to December 2013. They had no significant findings following upper gastrointestinal endoscopy. All subjects completed a questionnaire that addressed a frequency scale for symptoms of gastroesophageal reflux disease...
2017: Esophagus: Official Journal of the Japan Esophageal Society
https://www.readbyqxmd.com/read/28659302/higher-dietary-cholesterol-and-%C3%AF-3-fatty-acid-intakes-are-associated-with-a-lower-success-rate-of-helicobacter-pylori-eradication-therapy-in-japan
#14
Hiroaki Ikezaki, Norihiro Furusyo, Paul F Jacques, Motohiro Shimizu, Masayuki Murata, Ernst J Schaefer, Yoshihisa Urita, Jun Hayashi
Background: Helicobacter pylori infection is a known risk factor for duodenal ulcers, gastritis, and gastric cancer. The eradication of H. pylori is successful in treating these disorders; however, the success rate of eradication therapy is declining. There may be an interaction with nutrient intake to account for this decline. Objective: We investigated the influence of food and nutrient intake on H. pylori eradication therapy. Design: In this study, 4014 subjects underwent endoscopy, were tested for serum antibodies to H...
August 2017: American Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/28569272/gastric-adenocarcinoma
#15
REVIEW
Jaffer A Ajani, Jeeyun Lee, Takeshi Sano, Yelena Y Janjigian, Daiming Fan, Shumei Song
Gastric cancers, with gastric adenocarcinoma (GAC) as the most common histological type, impose a considerable global health burden. Although the screening strategies for early detection have been shown to be successful in Japan and South Korea, they are either not implemented or not feasible in most of the world, leading to late diagnosis in most patients. Helicobacter pylori infection contributes to the development of many endemic GACs, and pre-emptive eradication or early treatment of this bacterial infection might provide effective primary prevention...
June 1, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/28566587/the-superiority-of-vonoprazan-based-first-line-triple-therapy-with-clarithromycin-a-prospective-multi-center-cohort-study-on-helicobacter-pylori-eradication
#16
MULTICENTER STUDY
Soichiro Sue, Hirofumi Kuwashima, Yuri Iwata, Hiroyuki Oka, Isao Arima, Takehide Fukuchi, Katsuyuki Sanga, Yasuhiro Inokuchi, Yuniba Ishii, Masatomo Kanno, Masahiro Terada, Hitoshi Amano, Makoto Naito, Shigeru Iwase, Hiroshi Okazaki, Kazuto Komatsu, Atsushi Kokawa, Ichiro Kawana, Manabu Morimoto, Toshifumi Saito, Yosuke Kunishi, Akihiko Ikeda, Daisuke Takahashi, Haruo Miwa, Tomohiko Sasaki, Toshihide Tamura, Masaaki Kondo, Wataru Shibata, Shin Maeda
Objective We evaluated the safety and efficacy of vonoprazan-based amoxicillin and clarithromycin 7-day triple therapy (VAC) in comparison to proton pump inhibitor (PPI)-based (PAC) as a first-line treatment and vonoprazan-based amoxicillin and metronidazole 7-day triple therapy (VAM) in comparison to PPI-based (PAM) as a second-line treatment for the eradication of Helicobacter pylori in Japan. Methods We performed a non-randomized, multi-center, parallel-group study to compare first-line VAC to PAC and second-line VAM to PAM...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28216974/comparative-study-vonoprazan-and-proton-pump-inhibitors-in-helicobacter-pylori-eradication-therapy
#17
COMPARATIVE STUDY
Kouichi Sakurai, Hiroko Suda, Yumi Ido, Takayuki Takeichi, Ayako Okuda, Kiwamu Hasuda, Masahiro Hattori
AIM: To compare the effectiveness and safety of vonoprazan-based therapy with proton pump inhibitor (PPI)-based therapies to treat Helicobacter pylori (H. pylori). METHODS: We retrospectively analysed data from first-line (vonoprazan or PPI with 200 mg clarithromycin and 750 mg amoxicillin twice daily for 7 d) (n = 1353) and second-line (vonoprazan or PPI with 250 mg metronidazole and 750 mg amoxicillin twice daily for 7 d) (n = 261) eradication treatments for H...
January 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27803739/vonoprazan-based-therapy-for-helicobacter-pylori-eradication-experience-and-clinical-evidence
#18
REVIEW
Yuko Akazawa, Daisuke Fukuda, Yutaka Fukuda
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27698544/esomeprazole-or-rabeprazole-based-triple-therapy-eradicated-helicobacter-pylori-comparably-regardless-of-clarithromycin-susceptibility-and-cyp2c19-genotypes
#19
Tadayoshi Okimoto, Kazuhiro Mizukami, Ryo Ogawa, Kazuhisa Okamoto, Mitsutaka Shuto, Kensuke Fukuda, Masaaki Kodama, Kazunari Murakami
The aim of this study was to assess the efficacy of esomeprazole-based triple therapy compared with rabeprazole-based triple therapy according to CYP2C19 genotype and clarithromycin susceptibility status for first-line eradication therapy of Helicobacter pylori (H. pylori) in Japan. We enrolled 219 H. pylori-infected patients, and randomly allocated patients to the EAC group (esomeprazole 20 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily) or RAC group (rabeprazole 10 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily)...
September 2016: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/27689190/a-novel-potassium-competitive-acid-blocker-improves-the-efficacy-of-clarithromycin-containing-7-day-triple-therapy-against-helicobacter-pylori
#20
COMPARATIVE STUDY
Hisatsugu Noda, Seiji Noguchi, Takashi Yoshimine, Shigeki Goji, Kazunori Adachi, Yasuhiro Tamura, Shinya Izawa, Masahide Ebi, Sayuri Yamamoto, Naotaka Ogasawara, Yasushi Funaki, Makoto Sasaki, Kunio Kasugai
BACKGROUND AND AIMS: In Japan, 7-day triple therapy for Helicobacter pylori including clarithromycin (CAM) was approved in 2000. However, antibiotic resistance subsequently reduced this rate to an unacceptable level (70%). Vonoprazan, an orally bioavailable potassium-competitive acid blocker (P-CAB), was approved in Japan in 2014. This could improve eradication rates by increasing the intragastric pH, thus increasing bacterial antibiotic susceptibility. This study compared the efficacy of 7-day triple therapies that included CAM and vonoprazan or proton pump inhibitor (PPI)...
September 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
keyword
keyword
116998
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"